The safety of vedolizumab for the treatment of ulcerative colitis.
Novak, Gregor; Hindryckx, Pieter; Khanna, Reena; Jairath, Vipul; Feagan, Brian G.
Expert Opin Drug Saf
; 16(4): 501-507, 2017 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-28276855
A randomised phase I study of etrolizumab (rhuMAb ß7) in moderate to severe ulcerative colitis.
Vedolizumab bei Colitis ulcerosa und Morbus Crohn: eine Standortbestimmung.
Meta-analysis of the effectiveness and safety of vedolizumab for ulcerative colitis.
Anti-TNF-A therapy about infliximab and adalimamab for the effectiveness in ulcerative colitis compared with conventional therapy: a meta-analysis.
Etrolizumab for induction of remission in ulcerative colitis.
Integrin antagonists as potential therapeutic options for the treatment of Crohn's disease.
Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial.
Efficacy and safety of antiintegrin antibody for inflammatory bowel disease: a systematic review and meta-analysis.
Long-Term Benefit of Mesalamine Granules for Patients Who Achieved Corticosteroid-Induced Ulcerative Colitis Remission.
First trough level of infliximab at week 2 predicts future outcomes of induction therapy in ulcerative colitis-results from a multicenter prospective randomized controlled trial and its post hoc analysis.